Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.

被引：0
|
作者：
Lu, Nian
Jiang, Yao-Fei
Xia, Weixiong
Huang, Ying
Xie, Chuan-Miao
Xu, Cheng
Ye, Yan-Fang
Liu, Guo-Ying
Bei, Wei-Xin
Ke, Liang-Ru
Li, Wang-Zhong
Wang, Xin
Xie, Changqing
Liang, Hu
Xiang Yanqun
机构：
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc,Guangdong Key Lab Nasopharyngeal Carcino, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Dept Med Imaging, Ctr Canc, Guangzhou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg & Oncol,Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis,State Key Lab Resp Dis, Guangzhou, Peoples R China
[11] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, OH USA
[12] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6031
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.
    Kang, Hyunseok
    Ho, Alan Loh
    Muzaffar, Jameel
    Bowles, Daniel W.
    Kim, Sung-Bae
    Ahn, Myung-Ju
    Hanna, Glenn J.
    Worden, Francis P.
    Yun, Tak
    Norton, Steven
    Sankar, Neil
    Keam, Bhumsuk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
    Machiels, Jean-Pascal
    Subramanian, Somasundaram
    Ruzsa, Agnes
    Repassy, Gabor
    Lifirenko, Igor
    Flygare, Annika
    Sorensen, Per
    Nielsen, Tina
    Lisby, Steen
    Clement, Paul M. J.
    LANCET ONCOLOGY, 2011, 12 (04): : 333 - 343
  • [43] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
    Zhou, Caicun
    Li, Xingya
    Wang, Qiming
    Gao, Guanghui
    Zhang, Yiping
    Chen, Jianhua
    Shu, Yongqian
    Hu, Yanping
    Fan, Yun
    Fang, Jian
    Chen, Gongyan
    Zhao, Jun
    He, Jianxing
    Wu, Fengying
    Zou, Jianjun
    Zhu, Xiaoyu
    Lin, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (24) : 2753 - +
  • [45] A PHASE II STUDY ASSESSING SAFETY AND EFFICACY OF CABOZANTINIB FOR ADVANCED OR METASTATIC CERVICAL CARCINOMA AFTER PLATINUM TREATMENT FAILURE (CABOCOL STUDY)
    Coquan, Elodie
    Lequesne, Justine
    Colomba, Emeline
    Frenel, Jean-Sebastien
    Abdeddaim, Cyril
    D'Hondt, Veronique
    Castera, Marie
    Abadie-Lacourtoisle, Sophie
    Dubot, Coraline
    Brachet, Pierre-Emmanuel
    Leconte, Alexandra
    Clarlsse, Benedicte
    Joly, Florence
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A14 - A14
  • [46] Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
    Wang, Miao
    Zhou, Jiamin
    Xu, Weiqi
    Pan, Qi
    Mao, Anrong
    Zhang, Ning
    Feng, Yun
    He, Xigan
    Lin, Zhenhai
    Wang, Longrong
    Zhang, Yongfa
    Zhu, Hongxu
    Ding, Zhiwe
    Wang, Yixiu
    Yu, Bingran
    Zhang, Ti
    Wang, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 489 - 489
  • [47] OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib plus bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.
    Hope, Joanie M.
    Chen, Jian
    Wainszelbaum, Marisa
    Gupta, Divya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study
    Atkins, Michael B.
    Ravaud, Alain
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Kracht, Karolyn
    Puhlmann, Markus
    Weinreich, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [50] OPEN-LABEL PHASE II STUDY OF SORAFENIB plus DACARBAZINE IN PATIENTS WITH ADVANCED METASTATIC MELANOMA
    Gonzalez-Larriba, J. L.
    Guillem, V.
    Marmol, M.
    Valladares, M.
    Arrivi, A.
    Pastor, P.
    Garcia-Garcia, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
12345